腫瘤精準醫療合作與授權協議（2016-2025）

本報告全面深入分析了腫瘤精準醫療合作與許可協議，讓您以前所未有的方式了解全球領先的生物製藥公司簽署的腫瘤精準醫療協議。

這份經過全面修訂和更新的報告詳細介紹了2016年至2025年間的腫瘤精準醫療交易。

本報告詳細分析了企業達成腫瘤精準醫療協議的原因和方式。這些協議通常包含多個組成部分，從合作研發開始，逐步推進到成果的商業化。

本報告涵蓋合作、開發、研究和授權等內容。

本報告列出了自2016年以來宣布的879項腫瘤精準醫療交易。報告盡可能包含財務條款，並提供連結指向各方揭露的實際腫瘤精準醫療合作交易的線上記錄。此外，在可取得的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告的引言概述了腫瘤精準醫療領域的交易情況。

第一章概述了本報告。

第二章概述了自2016年以來腫瘤精準醫療領域的交易活動。

第三章概述了自2016年以來主要的腫瘤精準醫療交易，並依交易額列出。

第四章提供了腫瘤精準醫療交易領域最活躍的25家公司的完整列表，並附有簡要概述。隨後是腫瘤精準醫療交易的完整清單以及公開合約文件清單。

第五章對自2016年1月以來已完成或宣布的腫瘤精準醫療交易進行了全面深入的回顧，重點關注合約文件公開的案例。

第六章對自2016年1月以來已完成或宣布的腫瘤精準醫療合作交易進行了全面深入的回顧。本章依腫瘤精準醫療技術的具體類型進行組織。

本報告也包含大量表格和圖表，顯示了自2016年以來腫瘤精準醫療交易的趨勢和動態。

此外，我們還提供了一個全面的合約目錄，依公司名稱（依字母順序排列）、合約類型和治療靶點進行分類。每個合約標題都連結到合約記錄的線上版本，並在可用的情況下連結到合約文件，方便用戶根據需要輕鬆存取每個合約文件。

主要優勢

本報告 "腫瘤精準醫療合作研究與授權協議" 為讀者提供以下主要優勢：

• 了解自 2016 年以來的交易趨勢
• 瀏覽腫瘤精準醫療合作與授權協議
• 基準分析 - 確定交易市場價值
• 財務條款 - 首付款、里程碑付款、特許權使用費
• 依公司（A-Z）、協議類型和治療領域分類的合約目錄
• 以價值排名的主要交易
• 最活躍的交易撮合者
• 識別每筆交易的資產和條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款對合作公司的適用性
• 節省數百小時的研究時間

範圍

• "腫瘤精準醫療合作與許可協議" 報告旨在幫助讀者深入了解腫瘤精準醫療的發展趨勢以及全球主要生物製藥公司達成的協議結構。

本報告涵蓋：

• 生物製藥產業腫瘤精準醫療交易趨勢
• 製藥和生物技術公司腫瘤精準醫療交易記錄目錄
• 以交易金額排名的主要腫瘤精準醫療交易
• 最活躍的腫瘤精準醫療許可協議
• "腫瘤精準醫療合作研究與許可協議" 報告提供對現有協議記錄的全面訪問，包括合約文件（如有）。

分析協議有助於對以下方面進行盡職調查：

• 協議具體授予或選擇哪些權利？
• 協議實際授予合作夥伴哪些權利？
• 授予了哪些排他性權利？
• 交易的付款結構是什麼？
• 如何進行銷售和付款審計？
• 合約期限是多久？
• 如何定義合約的關鍵條款？
• 如何處理和歸屬知識產權？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止合約？
• 如果所有權發生變更，會發生什麼事？
• 如何就分授權和分包條款達成協議？
• 貴公司要求使用哪些標準條款？
• 哪些標準條款會因交易對手和交易類型而異？
• 貴公司合約受哪個司法管轄區管轄？

目錄

摘要整理

第一章：引言

第二章：腫瘤精準醫療交易趨勢

• 引言
• 歷年腫瘤精準醫療交易趨勢
• 腫瘤領域最活躍的精準醫療交易商
• 依交易類型劃分的腫瘤精準醫療交易趨勢
• 依行業劃分的腫瘤精準醫療交易趨勢
• 依行業劃分的腫瘤精準醫療交易趨勢
  • 腫瘤精準醫療交易趨勢的核心價值
  • 腫瘤精準醫療預付款安排
  • 腫瘤精準醫療交易里程碑付款
  • 腫瘤精準醫療特許權使用費費率

第三章：精準醫療引領腫瘤交易

• 引言
• 腫瘤領域頂尖精準醫療交易

第四章：腫瘤領域最活躍的精準醫療交易撮合者

• 引言
• 腫瘤領域最活躍的精準醫療交易撮合者
• 腫瘤領域最活躍的精準醫療公司簡介

第五章：腫瘤領域精準醫療交易目錄

• 引言
• 腫瘤領域精準醫療交易目錄

第六章：腫瘤領域精準醫療交易 - 依技術類型分類

• 交易目錄
• 腫瘤領域精準醫療交易目錄（依公司名稱，A-Z）
• 交易目錄 - 腫瘤精準醫療交易（依交易類型）
• 交易目錄 - 腫瘤精準醫療交易（依治療領域）
• 交易類型定義
• 關於研究公司
• 當前合作夥伴關係
• 當前協議
• 依目前合作夥伴關係劃分的最新報告標題

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 879 precision medicine in oncology deals announced since 2016 including financial terms where available including links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine in oncology dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine in oncology dealmaking since 2016.

Chapter 3 provides an overview of the leading precision medicine in oncology deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine in oncology dealmaking with a brief summary followed by a comprehensive listing of precision medicine in oncology deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine in oncology deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of precision medicine in oncology partnering deals signed and announced since Jan 2016. The chapter is organized by specific precision medicine in oncology technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine in oncology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse precision medicine in oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Precision Medicine in Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of precision medicine in oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Precision Medicine in Oncology Collaboration and Licensing Deals includes:

• Trends in precision medicine in oncology dealmaking in the biopharma industry
• Directory of precision medicine in oncology deal records covering pharmaceutical and biotechnology
• The leading precision medicine in oncology deals by value
• Most active precision medicine in oncology licensing dealmakers
• Precision Medicine in Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

• 2.1. Introduction
• 2.2. Precision medicine in oncology deals over the years
• 2.3. Most active precision medicine in oncology dealmakers
• 2.4. Precision medicine in oncology deals by deal type
• 2.5. Precision medicine in oncology deals by therapy area
• 2.6. Precision medicine in oncology deals by industry sector
• 2.7. Deal terms for precision medicine in oncology deals
  • 2.7.1 Precision medicine in oncology deals headline values
  • 2.7.2 Precision medicine in oncology deal upfront payments
  • 2.7.3 Precision medicine in oncology deal milestone payments
  • 2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

• 3.1. Introduction
• 3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

• 4.1. Introduction
• 4.2. Most active precision medicine in oncology dealmakers
• 4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

• 5.1. Introduction
• 5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

• Deal directory
• Deal directory - Precision medicine in oncology deals by company A-Z
• Deal directory - Precision medicine in oncology deals by deal type
• Deal directory - Precision medicine in oncology deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Precision medicine in oncology deals since 2016
• Figure 2: Active precision medicine in oncology dealmaking activity - 2016 - 2025
• Figure 3: Precision medicine in oncology deals by deal type since 2016
• Figure 4: Precision medicine in oncology deals by therapy area since 2016
• Figure 5: Precision medicine in oncology deals by industry sector since 2016
• Figure 6: Precision medicine in oncology deals with a headline value
• Figure 7: Precision medicine in oncology deals with an upfront value
• Figure 8: Precision medicine in oncology deals with a milestone value
• Figure 9: Precision medicine in oncology deals with a royalty rate value
• Figure 10: Top precision medicine in oncology deals by value since 2016
• Figure 11: Most active precision medicine in oncology dealmakers 2016 - 2025
• Figure 12: Precision medicine in oncology deals by technology type since 2016